|
|
||||||||
and MAPK
Departments of 1 Medicine and 2 Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, and 3 Ralph H. Johnson Veteran Affairs Medical Center, Charleston, South Carolina 29425
| |
ABSTRACT |
|---|
|
|
|---|
Accumulation of
extracellular matrix (ECM) is a hallmark feature of vascular disease.
We have previously shown that hyperglycemia induces the expression of
B2-kinin receptors in vascular smooth muscle cells (VSMC)
and that bradykinin (BK) and hyperglycemia synergize to stimulate ECM
production. The present study examined the cellular mechanisms through
which BK contributes to VSMC fibrosis. VSMC treated with BK
(10
8 M) for 24 h significantly increased
2(I) collagen mRNA levels. In addition, BK produced a
two- to threefold increase in
2(I) collagen promoter
activity in VSMC transfected with a plasmid containing the
2(I) collagen promoter. Furthermore, treatment of VSMC
with BK for 24 h produced a two- to threefold increase in the
secretion rate of tissue inhibitor of metalloproteinase 1 (TIMP-1). The
increase in
2(I) collagen mRNA levels and
2(I) collagen promoter activity, as well as TIMP-1
secretion, in response to BK were blocked by anti-transforming growth
factor-
(anti-TGF-
) neutralizing antibodies. BK
(10
8 M) increased the endogenous production of TGF-
1
mRNA and protein levels. Inhibition of the mitogen-activated protein
kinase (MAPK) pathway by PD-98059 inhibited the increase of
2(I) collagen promoter activity, TIMP-1 production, and
TGF-
1 protein levels observed in response to BK. These findings
provide the first evidence that BK induces collagen type I and TIMP-1
production via autocrine activation of TGF-
1 and implicate MAPK
pathway as a key player in VSMC fibrosis in response of BK.
collagen; tissue inhibitor of metalloproteinase 1; transforming
growth factor-
; mitogen-activated protein kinase
| |
INTRODUCTION |
|---|
|
|
|---|
VASCULAR SMOOTH MUSCLE CELL (VSMC) expansion and the resultant increased extracellular matrix (ECM) deposition play pivotal roles in the progression of atherogenesis (2). Increases in ECM components such as collagens types I and IV are found in plaque areas of aortas from type 1 diabetic patients (32). These changes in matrix composition may impair vascular function by changing VSMC from their contractile state to a synthetic state (5). Although the precise mechanisms underlying these changes are undefined, the interaction between arterial smooth muscle cells and the surrounding matrix suggests a dynamic system in which changes in composition and spatial organization of matrix itself may profoundly change the metabolic and proliferative activity of VSMC (34, 42). Collagen formation is the major contributor to the growth of atherosclerotic lesions (2). Of the various types of collagens, type I is the primary component of atherosclerotic plaque and is synthesized by arterial smooth muscle cells in response to growth factors (2). Thus matrix deposition is a characteristic part of the sclerotic process that contributes to vascular function impairment by disrupting normal cell-cell interaction and modifying tissue elasticity.
Among the factors that play a central role in vascular fibrosis is
transforming growth factor-
(TGF-
). TGF-
has been shown to
stimulate collagen expression in VSMC and also to influence the
expression of some matrix metalloproteinases (MMP) and their tissue
inhibitors (TIMPs). Since matrix deposition is the result of a balance
between synthesis and degradation of ECM components, it is conceivable
that the delicate balance between MMP and TIMP, as well as the rate of
ECM synthesis, determine the final matrix accumulation.
The localization of components of the kallikrein-kinin system within the vascular wall suggests this system has a role in the regulation of vascular tone, hypertension, and atherogenesis (22, 24). Kallikrein and its mRNA are expressed in isolated arteries and veins and in cultured VSMC (29, 33). Kininogen, the substrate for kinin generation by kallikrein, kininase activity, and B2-kinin receptors are present in VSMC (30). Thus locally generated kinins can act in an autocrine or paracrine fashion to influence vascular function. The physiological actions of bradykinin (BK) are mediated via generation of second messengers such as nitric oxide and eicosanoids (17, 36). BK relaxes VSMC through synthesis and release of nitric oxide from the endothelium, but in states of vascular injury in which endothelial integrity is compromised, BK can act directly on VSMC, to increase intracellular calcium and cause contraction (4).
The signaling pathways leading to VSMC fibrosis are just beginning to be studied and seem to be derived from multiple sources. Our recent data demonstrate that BK stimulates early mitogenic signals in VSMC. Through activation of its B2 receptors, BK stimulates activation and nuclear translocation of p42mapk and p44mapk and induces expression of c-fos and c-jun mRNA levels and formation of the AP-1 complex (11, 44). The cellular signals through which BK stimulates p42mapk and p44mapk activation and c-fos mRNA expression in VSMC involves activation of a calcium/calmodulin pathway, src kinase, protein kinase C, and generation of reactive oxygen species (14, 28, 44).
Therefore, the present studies were designed to explore the role of BK
in mediating VSMC fibrosis. We found that BK induces
2
chain of type I [
2(I)] collagen mRNA levels,
2(I) collagen promoter activity, and TIMP-1
production via autocrine activation of TGF-
1. In addition, our
findings demonstrate that BK signals via the mitogen-activated protein
kinase (MAPK) pathway to mediate its effects on
2(I)
collagen and TIMP-1 production. These findings provide the first
evidence for a potential role for BK in VSMC fibrosis.
| |
METHODS |
|---|
|
|
|---|
Cell culture.
Rat aortic VSMC from male Sprague-Dawley rats (Charles River
Laboratories, Wilmington, MA) were prepared by a modification of the
method of Majack and Clowes (21). A 2-cm segment of
thoracic aorta cleaned of fat and adventitia was incubated in 1 mg/ml
collagenase for 3 h at room temperature. The aorta was then cut
into small sections and placed into a culture flask for explantation in
minimal essential media (MEM) containing 10% FBS, 1% nonessential
amino acids, 100 mU/ml penicillin, and 100 µg/ml streptomycin
(Cellgro; Mediatech, Herndon, VA). Cells were incubated at 37°C in a
humidified atmosphere of 95% air-5% CO2. Medium was
changed every 3-4 days, and cells were passaged every 6-8
days by harvesting with trypsin-EDTA. Cell viability was assessed by
standard dye exclusion techniques using 1% trypan blue. VSMC were
identified by the following criteria. They stained positive for
intracellular cytoskeletal fibrils of
-actin and smooth muscle
cell-specific myosin (indicative of contractile cell) and negative for
factor VIII antigens. VSMC isolated by this procedure were homogenous
and were used in all studies between passages 2 and
6.
RNA extraction and Northern blotting. VSMC in 15-cm dishes were rendered quiescent by growing them in serum-free media for 48 h. Cells were then stimulated with agonists as indicated. Total RNA from the cells was extracted by the chloroform-phenol method (6). RNA concentration and purity were determined spectrophotometrically (Ultrospec III, Pharmacia) by absorbance at 260 and 280 nm. Total RNA (20 µg) was denatured at 65°C for 15 min and ran on 1.5% agarose gel in denaturing conditions. The gel was stained with ethidium bromide to determine the position of the 28S and 18S ribosomal RNA and to demonstrate that similar amounts of intact RNA were used for each sample. Total RNA was transferred from the gel to Nytran membrane filters (Schleicher and Schuell, Keene, NH) by a pressure transducer (PosiBlot; Stratagene, La Jolla, CA), prehybridized for 2 h, and hybridized at 55°C for 18-24 h with nick-translated cDNA probes labeled with 32P using a nick-translation kit (Bethesda Research Laboratories, Bethesda, MD). The hybridized membranes were washed and exposed to film. Autoradiographs (Kodak XAR-5 film, Eastman Kodak, Rochester, NY) of the membranes were obtained and scanned, and the intensities of the bands were quantified by NIH image 1.61/68k.
TGF-
1 protein level determination.
VSMC were cultured in six-well plates (9.6 cm2/well). At
70% confluence, cells were serum starved by the changing of the
serum-free media four times within 24 h. Cells were then
stimulated for 48 h with 10
8 M BK, in presence or
absence of 40 µM of PD-98059, in exactly 1.5 ml. TGF-
1
protein levels were determined by colorimetric enzyme-linked
immunosorbent assay kit (ELISA; R&D Systems, Minneapolis, MN) in the
conditioned media that were activated by HCl (to measure both active
and latent TGF-
1) according to the manufacturer instructions, and
expressed as picograms per milliliter.
Transfection of VSMC with the
2(I) collagen
promoter.
VSMC were transfected by the calcium chloride method with a plasmid
containing the
2(I) collagen promoter attached to the chloramphenicol acetyl transferase (CAT) gene (
353 COL1A2 CAT); the
plasmid was obtained from Promega (Madison, WI), prepared as described
by Tamaki et al. (41), purified by double cesium chloride
purification, and stored at 4°C. The plasmid (20 µg of plasmid DNA)
in a 2 M CaCl2 solution was mixed with an equal volume of
2× DNA precipitation buffer (3 Prime
5 Prime Inc., Boulder, CO) and
incubated for 30 min before addition to the cells. After 16 h of
incubation, the culture medium was changed to 1% FBS in MEM. Two hours
later, the cells were stimulated for 24 h as indicated. The cells
were then washed in PBS and resuspended in 0.25 M Tris, pH 8.0. The CAT
was extracted from the cells by four cycles of freezing-thawing and
centrifugation at 13,800 g for 15 min. Protein concentrations were determined in each cell extract by Bio-Rad protein
assay (Bio-Rad, Hercules, CA), and 10-20 µg of proteins from
each dish were used for CAT activity assay. CAT activity of each sample
was performed in presence of 2.5 mg/ml of butyryl-CoA and
[14C]chloramphenicol incubated for 90 min at 37°C.
Acetylated chloramphenicol was extracted by
tetramethylpentadecane/xylene (2:1), and radioactivity was measured in
a BetaMax counter (ICN, Costa Mesa, CA). In some experiments, 5 µg of the pSV-
-galactosidase control vector (Promega) was
cotransfected to normalize for transfection efficiency.
-Galactosidase activity assays were measured according to the
manufacturer instructions
Western blotting of TIMP-1. VSMC in 60-mm dishes were rendered quiescent by growing them in serum-free media for 24 h. Cells were then stimulated as indicated. The conditioned media were collected after 24 h and concentrated by lyophilization. Proteins were determined by Bio-Rad protein assay and resolved on SDS-PAGE. The separated proteins in the gel were transferred to Immobilon-P membrane (Millipore, Bedford, MA) and immunoblotted with goat polyclonal anti-rat TIMP-1 specific antibody (1:2,000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). The blots were revealed by anti-goat IgG antibody conjugated with alkaline phosphatase (1:6,000 dilution, Santa Cruz Biotechnology) and CDP-Star chemiluminescent system (NEN Life Sciences Products, Boston, MA). The membranes were exposed to film (X-Omat LS, Kodak). Films were scanned, and the intensities of the bands were quantified by NIH image 1.61/68k.
Phospho-MAPK immunoblots. To measure MAPK activity, 20-25 µg of soluble protein obtained from cell lysates were subjected to SDS-PAGE. The separated proteins in the gel were transferred to polyvinylidene difluoride membranes, and immunoblotted with rabbit polyclonal phospho-specific MAPK antibodies that specifically recognize tyrosine phosphorylated p42mapk and p44mapk (New England Biolabs, Beverly, MA). The phospho-MAPK antibody was used at 1:6,000 dilution, whereas the control antibody, which recognizes total MAPK, was used at 1:4,000 dilution. The membranes were incubated overnight with the antibody buffer (TBS, 0.05% Tween 20, 1% BSA), washed in TBS-0.05% Tween 20, and exposed to goat anti-rabbit horseradish peroxidase-conjugated IgG (1:5,000) in antibody buffer for 1 h. Immunoreactive bands were visualized by a chemiluminescent method (Renaissance, New England Biolabs) using Kodak X-LS film.
Statistical analysis. Data are expressed as means ± SE and were analyzed by ANOVA and by using student's t-test for unpaired analysis. Differences were considered significant if P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Induction of
2(I) collagen expression by BK.
To investigate whether BK induces ECM formation, we measured
2(I) collagen mRNA expression in VSMC treated with BK
(10
8 M) for 24 h. As shown in Fig.
1A, BK produced a significant
increase in
2(I) collagen mRNA levels, expressed
relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA. The
2(I) collagen mRNA levels were increased to 160% of control VSMC (BK vs. control, P < 0.003, n = 3).
|
2(I) collagen gene by measuring its effect on the
activity of
2(I) collagen promoter. VSMC transfected
with a plasmid containing the
2(I) collagen promoter
were stimulated for 24 h with either BK (10
8 M) or
TGF-
1 (1 ng/ml) as positive control. The CAT activity (used as a
reporter for the activity of the collagen promoter) was determined in
the cell lysate.
The results (Fig. 1B) demonstrate for the first time that BK
can directly increase the activity of the collagen promoter. BK
produced a 2.5-fold increase in
2(I) collagen promoter
activity, whereas TGF-
1 produced a fourfold increase (control vs. BK
or TGF-
1, P < 0.005, n = 8 experiments).
Induction of TGF-
1 expression by BK.
To define the cellular mechanisms through which BK increased collagen
expression, the ability of BK to stimulate the endogenous production of
TGF-
was examined. We measured the TGF-
1 mRNA levels in VSMC
treated with BK (10
8 M) for various times. BK treatment
resulted in a significant increase in TGF-
1 mRNA levels/GAPDH mRNA
levels above control. This increase in TGF-
1 was observed as early
as 4 h, maintained at 6 h, and returned to normal values by
24 h (P < 0.02, BK vs. 0 h,
n = 4 experiments, Fig.
2).
|
Role of TGF-
in BK-induced
2(I) collagen
expression.
To further define the role of TGF-
in BK signaling, we examined
whether the increase in
2(I) collagen mRNA levels or
promoter activity in response to BK are mediated via autocrine
activation of TGF-
. VSMC were treated with BK (10
8 M)
for 24 h in the presence and absence of neutralizing anti-TGF-
antibodies (20 µg/ml, R&D Systems). This concentration of
anti-TGF-
antibody has been shown to neutralize the effects of
TGF-
on mesangial cell proliferation and matrix formation (39,
45). The results shown in Fig.
3A indicate that the ability
of BK to induce
2(I) collagen mRNA levels is blocked by
the anti-TGF-
neutralizing antibody (P < 0.05, BK
vs. BK+TGF-
neutralizing antibody, n = 3). We also
examined the effects of TGF-
neutralizing antibody on VSMC
transfected with the
2(I) collagen promoter and
stimulated with BK (10
8 M) for 24 h. Although we
have observed differences in the magnitude of response to BK between
different cell lines, once again, BK produced a significant increase in
CAT activity compared with unstimulated control cells (BK vs. control,
P < 0.01, n = 5, Fig. 3B).
This increase in CAT activity in response to BK stimulation was
completely blocked in the presence of anti-TGF-
neutralizing antibody. Anti-TGF-
neutralizing antibody had no significant effect
on basal CAT activity (Fig. 3B).
|
BK increases TIMP-1 secretion via a TGF-
-dependent mechanism.
TIMPs are proteins that regulate the activity of MMPs and play an
integral part in the turnover rate of ECM under physiological and
pathological conditions (13). Thus it is conceivable that VSMC matrix accumulation is the net result of signals that promote increased TIMP activity. To address this possibility, we examined the
effects of BK on the secretion rate of TIMP-1 in VSMC and explored the
role of TGF-
in mediating the effects of BK on TIMP-1 production.
VSMC were stimulated for 24 h with either BK (10
8 M)
or TGF-
1 (1 ng/ml), as positive control, in the presence and absence
of anti-TGF-
neutralizing antibody (20 µg/ml). The conditioned
media were analyzed by Western blotting for TIMP-1 using specific
anti-TIMP-1 antibody (1:2,000 dilution, Santa Cruz Biotechnology). The
results shown in Fig. 4 demonstrate that
both BK and TGF-
1 produced a significant increase in TIMP-1
production in VSMC (P < 0.05, control vs. BK or
TGF-
1, n = 5). This increase in TIMP-1 production in
response to either BK or TGF-
1 was completely blocked by the
anti-TGF-
neutralizing antibody, whereas the antibody alone had no
effect on basal TIMP-1 production (Fig. 4).
|
Activation of p42mapk and p44mapk by BK.
MAPKs belong to the group of serine-threonine kinases that are rapidly
activated in response to growth factors and appear to integrate
multiple intracellular signals transmitted by various second
messengers. To understand the signal transduction events mediated by
BK, we examined its effects on MAPK activation. Treatment of VSMC with
10
8 M BK for 5 min resulted in a rapid increase in
tyrosine phosphorylation of p42mapk and
p44mapk, compared with unstimulated cells (Fig.
5). However, in the presence of the MAPK
kinase inhibitor PD-98059 (40 µM), the increase in MAPK
phosphorylation in response to BK was reduced. This finding is
consistent with our previous observations demonstrating that BK
activates MAPK in a concentration and time-dependent manner (28,
44).
|
Induction of TGF-
1 by BK is mediated via a MAPK-dependent
pathway.
To determine whether the increase in TGF-
1 mRNA in response to BK
translates into an increase in TGF-
1 protein levels, TGF-
1 protein levels were measured in the conditioned media of VSMC stimulated with BK (10
8 M). As shown in Fig.
6, BK treatment resulted in a significant increase in TGF-
1 levels, compared with unstimulated control cells
(84.5 ± 6.1 vs. 30.8 ± 2.9 pg/ml, BK vs. control,
respectively, P < 0.0001, n = 5). To
evaluate whether activation of MAPK modulates the BK-induced increase
in TGF-
1 protein levels we observed, VSMC were treated with BK
(10
8 M) in the presence of the MAPK inhibitor, PD-98059.
The results shown in Fig. 6 demonstrate that inhibition of the MAPK
pathway by PD-98059 completely eliminates the response of BK to
stimulate TGF-
1 protein levels (84.5 ± 6.1 vs. 37.7 ± 2.7 pg/ml, BK vs. BK+PD-98059, P < 0.0001, n = 5).
|
Role of MAPK in BK-induced
2(I) collagen and TIMP-1
expression.
To examine whether activation of p42mapk and
p44mapk modulates the increase in
2(I)
collagen promoter activity in response to BK, VSMC transfected with the
2(I) collagen promoter were pretreated with the MAPK
kinase inhibitor PD-98059 (40 µM) for 30 min, followed by BK
(10
8 M) stimulation for 24 h. In the absence of
PD-98059, BK produced a significant increase in CAT activity compared
with unstimulated control cells (BK vs. control, P < 0.001, n = 5, Fig.
7A). This increase in CAT
activity in response to BK stimulation was reduced significantly in the
presence of MAPK kinase inhibitor (P < 0.04, BK vs.
BK+PD-98059, Fig. 7A). The MAPK kinase inhibitor had no significant effect on basal CAT activity (Fig. 7A).
|
8 M) stimulation for 24 h.
The release of TIMP-1 protein levels into the conditioned media was
measured by Western blots using specific anti-TIMP-1
antibodies (1:2,000 dilution). BK produced a threefold
increase in the secretion rate of TIMP-1 into the media compared with
unstimulated cells (BK vs. C, P < 0.05, n = 4) (Fig. 7B). However, inhibition of
MAPK activity significantly decreased TIMP-1 secretion in response to
BK (BK vs. BK+PD-98059, P < 0.05, n = 4). The MAPK kinase inhibitor did not significantly alter basal
secretion rate of TIMP-1.
| |
DISCUSSION |
|---|
|
|
|---|
The role of locally generated vasoactive factors in regulating
vascular tone and structure under normal and pathological conditions has been increasingly emphasized. Among these factors, BK and angiotensin II are often considered to have opposite effects on vessel
wall with regard to vascular reactivity and arterial compliance. Although the role of angiotensin II has been extensively studied with
regard to vascular injury and remodeling, the precise role of BK on
VSMC structure and the resultant fibrosis has not been well studied. In
the present study we have demonstrated that BK induces the expression
and transcriptional activation of
2(I) collagen gene in
VSMC. In addition, we have also shown that BK stimulates the production
and secretion rate of TIMP-1. The increase in
2(I)
collagen mRNA levels,
2(I) collagen promoter activity, and TIMP-1 production in response to BK are mediated via autocrine activation of TGF-
1. Moreover, the increase in
2(I)
collagen promoter activity, TGF-
1, and TIMP-1 production by
BK involves activation of the MAPK pathway. These findings
provide the first evidence that BK stimulates several key signaling
pathways that participate in matrix dysregulation in VSMC.
Type I collagen represents up to two-thirds of total collagen, and
total collagen constitutes about 60% of total atherosclerotic plaque
protein composition (26, 37). Collagen type I is a heterotrimer consisting of two
1(I) chains and one
2(I) chain, which are expressed in a coordinated manner.
The expression of type I collagen is strictly regulated through
development and is tissue specific (31). In the present
study, we have shown that BK stimulates the mRNA levels of
2(I) collagen in VSMC. To begin to understand the
mechanism of this collagen regulation by BK, we examined the effects of
BK on VSMC transfected with the
2(I) collagen promoter.
Our results demonstrate that BK stimulates the
2(I)
collagen promoter activity, indicating that the increase in
2(I) collagen mRNA levels in response to BK are mediated
via transcriptional regulation. The
2(I) collagen
promoter is regulated by transcription factors such as SP1, SP3, CBF,
and AP-1 (7, 41). We have previously shown that
BK can induce the expression of protooncogene c-fos and c-jun, and the
formation of AP-1 complex transcription factor (15). The
increase in c-fos mRNA levels and the formation of AP-1 complex in
response to BK were mediated via activation of p42mapk and
p44mapk pathway (11, 28). In this regard, our
data demonstrate that activation of p42mapk and
p44mapk plays a critical role in mediating the effects of
BK on collagen regulation. Thus inhibition of the MAPK pathway
significantly reduced the increase in
2(I) collagen
promoter activity in response to BK. Therefore, one can speculate that
activation of BK receptors in VSMC in response to BK results in
activation of the MAPK pathway, which in turn results in the formation
of the transcription factor AP-1, which leads to transcriptional
activation of
2(I) collagen gene.
TGF-
is the most potent and consistent activator of collagen
synthesis in VSMC (9). It increases the level of
steady-state mRNA of
2(I) and
1(III) collagen in VSMC
(1). In models of atherosclerosis such as rat balloon
injury, TGF-
was implicated as the factor responsible for the
increase in collagen production. Transfection of TGF-
gene into pig
artery results in enhanced collagen type I production and accumulation
(27). In the model of rat balloon injury, the injection of
recombinant soluble TGF-
type II receptor caused a marked reduction
in mRNA levels for collagen type I and III, thus indicating the role of
TGF-
type II receptor in the fibrotic activity of TGF-
(38). Similarly, in VSMC, a dominant-negative mutation of
TGF-
type II receptor abrogated the enhanced production of collagen
type I induced by TGF-
(46). However, the response of
VSMC to TGF-
can be different according to the cell origin
(43). Hence, TGF-
inhibits the cell growth and
increases slightly the collagen synthesis in normal VSMC, whereas it
stimulates cell growth and markedly induces collagen synthesis in VSMC
isolated from atherosclerotic lesions (23). In the present
study we have shown that TGF-
plays a crucial role in mediating the
effects of BK on matrix dysregulation. Our findings demonstrate that BK
stimulates
2(I) collagen mRNA levels and
2(I) collagen promoter activity via autocrine activation of TGF-
. Support for such a notion comes from the findings that addition of anti-TGF-
neutralizing antibody reduces the mRNA levels
and promoter activity of
2(I) collagen in VSMC in
response to BK. In addition, our findings demonstrate that BK induced
the expression of TGF-
1 mRNA levels in VSMC as early as 4 h and
also resulted in a marked increase in TGF-
1 protein levels. These findings provide the first evidence that BK stimulates collagen type I
production in VSMC via autocrine induction of TGF-
.
Matrix deposition can be viewed as the result of the balance between
synthesis and degradation of ECM components. Matrix is degraded by
MMPs, a family of neutral zinc proteases, which include the
collagenases that degrade type I, III, and IV collagens, the gelatinases, and the stromelysins (10). The matrix
proteases activity is blocked by a group of endogenous inhibitory
proteins termed TIMP, which include TIMP-1, -2, -3, and -4 (13). Thus it is conceivable that the delicate balance
between MMP and TIMP, as well as the rate of ECM synthesis, determines
the final fate of matrix accumulation. TIMP-1 is a small glycoprotein
synthesized by VSMC, which inhibits all the members of the MMP family
and has been shown to participate in various physiological processes that involve tissue remodeling (13). The promoter of
TIMP-1 contains multiple response elements in the 5' region of the
gene, including an AP-1-binding site (20). No studies have
addressed the effect of BK on TIMP-1 regulation in VSMC. Our study
indicates that BK stimulates the production and secretion of TIMP-1 in
VSMC and provides an additional pathway through which BK can influence ECM regulation. Since TGF-
has been shown to stimulate the
production of TIMP-1, we sought to determine whether BK stimulates
TIMP-1 production via autocrine activation of TGF-
. Addition of
neutralizing antibody to TGF-
completely eliminated the increase in
TIMP-1 production in response to BK, thus implicating TGF-
as a
principal stimulator of TIMP-1 by BK in VSMC.
Although the cellular mechanisms through which BK mediates TIMP-1 production in VSMC are not defined, our results suggest a role for the MAPK pathway. Pretreatment of VSMC with the cell-permeable inhibitor of MAPK kinase significantly reduced the increase in TIMP-1 production in response to BK challenge, thus suggesting a role for p42mapk and p44mapk in modulating the production of TIMP-1 by BK. Another recent study has shown that the induction of TIMP-1 gene expression in fibroblasts in response to retinoic acid is also mediated via activation of p42mapk and p44mapk (3).
The role of MAPK in vascular dysfunction is just beginning to be
emphasized. The p42mapk and p44mapk members of
the MAPK family belong to a group of serine/threonine kinases that are
rapidly activated in response to growth factor stimulation. They
integrate multiple signals from various second messengers leading to
cellular proliferation and differentiation (8, 40). The
activated MAPK can translocate to the nucleus, where it is thought to
regulate the expression of transcription factors such as c-fos through
the phosphorylation of the transcription factor p62TCF and the
formation of AP-1 binding site (12). Recently, it has been
shown that MAPK activity is transiently activated following vessel wall
injury, whereas MAPK phosphatase-1 is decreased (18, 19).
In a model of myocardial infarction, MAPK activity was increased, along
with the mRNA levels of TGF-
and collagen types I and III
(35). In addition, NIH 3T3 cells transfected with a
dominant-negative mutant for MAPK kinase reduced the increase in collagen type I promoter activity in response TGF-
(25). In the present study we have shown that BK mediates
its fibrotic signals in VSMC via activation of the MAPK pathway.
Inhibition of MAPK reduced the increase in
2(I) collagen
promoter activity, TGF-
1 protein levels, and production of TIMP-1 in
response to BK. Other studies also support a role for MAPK in
modulating the effects of TGF-
on fibronectin production in VSMC
(16).
In summary, our results suggest that BK initiate multiple signals that
can result in fibrosis of VSMC. Our findings demonstrate that treatment
of VSMC with BK results in an increase in
2(I) collagen
mRNA levels and promoter activity and an increase in the production of
TIMP-1. The increase in
2(I) collagen promoter activity
and TIMP-1 production in response to BK are mediated via autocrine
activation of TGF-
and via activation of the MAPK pathway. The
significance of these findings to the in vivo actions of BK and the
vascular wall changes associated with injury or atherosclerosis is
unclear at the present time. Further understanding of the cellular and
molecular mechanisms by which BK might modulate vascular fibrosis, a
process obligatory to the development of atherosclerosis, could lead to
the development of new strategies for intervention and treatment of
vascular diseases.
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by National of Institutes of Health Grants HL-55782 and DK-46543, a Research Award from the American Diabetes Association (to A. A. Jaffa), a Merit Review Grant from the Research Service of the Department of Veterans Affairs (to R. K. Mayfield), a postdoctoral Award from the Juvenile Diabetes Foundation International (to V. Velarde), by National Heart, Lung, and Blood Institute Training Fellowship HL-07260 (to J. T. Christopher), and by a postdoctoral fellowship award from the Medical University of South Carolina (to C. D. Douillet).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: A. A. Jaffa, Dept. of Medicine, Endocrinology-Diabetes-Medical Genetics, Medical Univ. of South Carolina, 114 Doughty St., PO Box 250776, Charleston, SC 29425 (E-mail: jaffaa{at}musc.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 17 February 2000; accepted in final form 25 July 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Amento, EP,
Ehsani N,
Palmer H,
and
Libby P.
Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.
Arterioscler Thromb
11:
1223-1230,
1991
2.
Barnes, MJ.
Collagens in atherosclerosis.
Coll Relat Res
5:
65-97,
1985[Web of Science][Medline].
3.
Bigg, HF,
McLeod R,
Waters J,
Cawston TE,
Nolan JF,
and
Clark IM.
Induction of human tissue inhibitor of metalloproteinase-1 gene expression by all-trans retinoic acid in combination with basic fibroblast growth factor involves both p42/44 and p38 MAP kinases.
Ann NY Acad Sci
878:
506-509,
1999[Web of Science][Medline].
4.
Briner, VA,
Tsai P,
and
Schrier RW.
Bradykinin: potential for vascular constriction in the presence of endothelial injury.
Am J Physiol Renal Fluid Electrolyte Physiol
264:
F322-F327,
1993
5.
Campbell, GR,
Campbell JH,
Ang AH,
Campbell IL,
Horrigan S,
Manderson JA,
Mosse PRL,
and
Rennick RA.
Phenotypic changes in smooth muscle cells of human atherosclerotic plaques.
In: Pathophysiology of the Atherosclerotic Plaque, edited by Glagove S,
Newman WP,
and Schaffer SA.. New York: Springer-Verlag, 1990, p. 69-93.
6.
Chirgwin, JJ,
Przbyla AE,
MacDonald RJ,
and
Rutter WJ.
Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases.
Biochemistry
18:
5294-5299,
1979[Medline].
7.
Chung, KY,
Agarwal A,
Uitto J,
and
Mauviel A.
An AP-1 binding sequence is essential for regulation of the human
2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta.
J Biol Chem
271:
3272-3278,
1996
8.
Cobb, MH,
and
Goldsmith EJ.
How MAP kinases are regulated.
J Biol Chem
270:
14843-14846,
1995
9.
Davidson, JM,
Zoia O,
and
Liu JM.
Modulation of transforming growth factor-beta 1 stimulated elastin and collagen production and proliferation in porcine vascular smooth muscle cells and skin fibroblasts by basic fibroblast growth factor, transforming growth factor-alpha, and insulin-like growth factor-I.
J Cell Physiol
155:
149-156,
1993[Web of Science][Medline].
10.
Dollery, CM,
McEwan JR,
and
Henney AM.
Matrix metalloproteinases and cardiovascular disease.
Circ Res
77:
863-868,
1997
11.
El-Dahr, SS,
Dipp S,
and
Baricos WH.
Bradykinin stimulates the ERK-ELK-1-Fos/AP-1 pathway in mesangial cells.
Am J Physiol Renal Physiol
275:
F343-F352,
1998
12.
Gille, H,
Sharrocks AD,
and
Shaw PE.
Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter.
Nature
358:
414-417,
1992[Medline].
13.
Gomez, DE,
Alonso DF,
Yoshiji H,
and
Thorgeirsson UP.
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
Eur J Cell Biol
74:
111-122,
1997[Web of Science][Medline].
14.
Greene, EL,
Velarde V,
and
Jaffa AA.
Role of reactive oxygen species in bradykinin induced mitogen-activated protein kinase and c-fos induction in vascular cells.
Hypertension
35:
942-947,
2000
15.
Jaffa, AA,
Ullian ME,
Shankavaran U,
Rosenzweig SA,
and
Mayfield RK.
Bradykinin induces vascular smooth muscle cell proliferation (Abstract).
Clin Res
42:
108,
1994.
16.
Kaiura, TL,
Itoh H,
and
Kent KC.
The role of mitogen-activated protein kinase and protein kinase C in fibronectin production in human vascular smooth muscle cells.
J Surg Res
84:
212-217,
1999[Web of Science][Medline].
17.
Kichuk, MR,
Seyedi N,
Zhang X,
Marboe CC,
Michler RE,
Addonizio LJ,
Kaley G,
Nasjletti A,
and
Hintze TH.
Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation.
Circulation
94:
44-51,
1996
18.
Lai, K,
Wang H,
Lee WS,
Jain MK,
and
Haber E.
Mitogen-activated protein kinase phosphatase 1 in rat arterial smooth muscle cell proliferation.
J Clin Invest
98:
1560-1567,
1996[Web of Science][Medline].
19.
Lille, S,
Daum G,
Clowes MM,
and
Clowes AW.
The regulation of p42/p44 mitogen-activated protein kinase in the injured rat carotid artery.
J Surg Res
70:
178-186,
1997[Web of Science][Medline].
20.
Logan, SK,
Garabedian MJ,
Campbell CE,
and
Werb Z.
Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors.
J Biol Chem
271:
774-782,
1996
21.
Majack, RA,
and
Clowes AW.
Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans.
J Cell Physiol
118:
253-256,
1984[Web of Science][Medline].
22.
Margolius, HS.
Kallikrein and kinins. Some unanswered questions about system characteristics and roles in human disease.
Hypertension
26:
221-229,
1995
23.
McCaffrey, TA,
Consigli S,
Du B,
Falcone DJ,
Sanborn TA,
Spokojny AM,
and
Bush HL.
Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.
J Clin Invest
96:
667-675,
1995.
24.
Mombouli, JV,
and
Vanhoutte PM.
Kinins and endothelial control of vascular smooth muscle.
Annu Rev Pharmacol Toxicol
35:
579-705,
1995.
25.
Mucsi, I,
Skorecki KL,
and
Goldberg HJ.
Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta1 on gene expression.
J Biol Chem
271:
16567-16572,
1996
26.
Murata, K,
Motayama T,
and
Kotake C.
Collagen types in various layers of the human aorta and their changes with the atherosclerotic process.
Atherosclerosis
60:
251-262,
1986[Web of Science][Medline].
27.
Nabel, EG,
Schum L,
Pompili VJ,
Yang ZY,
San H,
Shu HB,
Liptay S,
Gold L,
Gordon D,
and
Derynck R.
Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia.
Proc Natl Acad Sci USA
90:
10759-10763,
1993
28.
Naidu, PS,
Velarde V,
Kappler CS,
Young RC,
Mayfield RK,
and
Jaffa AA.
Calcium-calmodulin mediates bradykinin-induced MAPK phosphorylation and c-fos induction in vascular cells.
Am J Physiol Heart Circ Physiol
277:
H1061-H1068,
1999
29.
Nolly, H,
Carretero OA,
and
Scicli AG.
Kallikrein release by vascular tissue.
Am J Physiol Heart Circ Physiol
265:
H1209-H1214,
1993
30.
Oza, N,
Schwartz JH,
Goud DH,
and
Levinsky NG.
Rat aortic smooth muscle cells in culture express kallikrein, kininogen and bradykininase activity.
J Clin Invest
85:
597-600,
1990.
31.
Ramirez, F,
and
Di Liberto M.
Complex and diversified regulatory programs control the expression of vertebrate collagen genes.
FASEB J
4:
1616-1623,
1990[Abstract].
32.
Rasmussen, LM,
and
Ledet T.
Aortic collagen alternations in human diabetes mellitus. Changes in basement membrane collagen content and the susceptibility of total collagen to cyanogen bromide solubilization.
Diabetologia
36:
445-453,
1993[Web of Science][Medline].
33.
Saed, G,
Carretero OA,
MacDonald RJ,
and
Scicli AG.
Kallikrein messenger RNA in arteries and veins.
Circ Res
67:
510-516,
1990
34.
Scott-Burdent, T,
Resnik TJ,
Burgin M,
and
Buhler FR.
Extracellular matrix: differential influence on growth and biosynthesis patterns of VSMC from SHR and WKY rats.
J Cell Physiol
141:
267-274,
1989[Web of Science][Medline].
35.
Shimizu, N,
Yoshiyama M,
Omura T,
Hanatani A,
Kim S,
Takeuchi K,
Iwao H,
and
Yoshikawa J.
Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats.
Cardiovasc Res
38:
116-124,
1998
36.
Siragy, HM,
Jaffa AA,
and
Margolius HS.
Bradykinin B2 receptors modulates renal prostaglandin E2 and nitric oxide.
Hypertension
29:
757-762,
1997
37.
Smith, EB.
The influence of age and atherosclerosis on the chemistry of aortic intima.
J Atheroscler Res
5:
241-248,
1965.
38.
Smith, JD,
Bryant SR,
Couper LL,
Vary CP,
Gotwals PJ,
Koteliansky VE,
and
Lindner V.
Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth.
Circ Res
84:
1212-1222,
1999
39.
Studer, RK,
Negrete H,
Craven PA,
and
DeRubertis FR.
Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-
bioactivity in mesangial cells.
Kidney Int
48:
422-430,
1995[Web of Science][Medline].
40.
Su, B,
and
Karin M.
Mitogen-activated protein kinases cascade and regulation of gene expression.
Curr Opin Immunol
8:
402-411,
1996[Web of Science][Medline].
41.
Tamaki, T,
Ohnishi K,
Hartl C,
LeRoy EC,
and
Trojanowska M.
Characterization of a GC-rich region containing Sp1 binding site(s) as a constitutive responsive element of the alpha 2(I) collagen gene in human fibroblasts.
J Biol Chem
270:
4299-4304,
1995
42.
Thie, M,
Harrach B,
Schonherr E,
Kresse H,
Robenek H,
and
Rauterberg J.
Responsiveness of aortic smooth muscle cells to soluble growth mediators is influenced by cell-matrix contact.
Arterioscler Thromb
13:
994-1004,
1993
43.
Thieszen, SL,
Dalton M,
Gadson PF,
Patterson E,
and
Rosenquist TH.
Embryonic lineage of vascular smooth muscle cells determines responses to collagen matrices and integrin receptor expression.
Exp Cell Res
227:
135-145,
1996[Web of Science][Medline].
44.
Velarde, V,
Ullian ME,
Morinelli TA,
Mayfield RK,
and
Jaffa AA.
Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells.
Am J Physiol Cell Physiol
277:
C253-C261,
1999
45.
Wolf, G,
Sharma K,
Chen Y,
Ericksen M,
and
Ziyadeh FN.
High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-
.
Kidney Int
42:
647-656,
1992[Web of Science][Medline].
46.
Yamamoto, H,
Ueno H,
Ooshima A,
and
Takeshita A.
Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture.
J Biol Chem
271:
16253-16259,
1996
This article has been cited by other articles:
![]() |
Y. Asano and M. Trojanowska Phosphorylation of Fli1 at Threonine 312 by Protein Kinase C {delta} Promotes Its Interaction with p300/CREB-Binding Protein-Associated Factor and Subsequent Acetylation in Response to Transforming Growth Factor {beta} Mol. Cell. Biol., April 1, 2009; 29(7): 1882 - 1894. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chao, H.-J. Li, Y.-Y. Yao, B. Shen, L. Gao, G. Bledsoe, and L. Chao Kinin Infusion Prevents Renal Inflammation, Apoptosis, and Fibrosis via Inhibition of Oxidative Stress and Mitogen-Activated Protein Kinase Activity Hypertension, March 1, 2007; 49(3): 490 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S Hopkinson, K. I Eleftheriou, J. Payne, A. H Nickol, E. Hawe, J. Moxham, H. Montgomery, and M. I Polkey +9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 912 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sohn, Y. Tan, B. Wang, R. L. Klein, M. Trojanowska, and A. A. Jaffa Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1624 - H1634. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Del Rosso, O Distler, A F Milia, C Emanueli, L Ibba-Manneschi, S Guiducci, M L Conforti, S Generini, A Pignone, S Gay, et al. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement Ann Rheum Dis, March 1, 2005; 64(3): 382 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. TSCHOPE, T. WALTHER, J. KONIGER, F. SPILLMANN, D. WESTERMANN, F. ESCHER, M. PAUSCHINGER, J. B. PESQUERO, M. BADER, H.-P. SCHULTHEISS, et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene FASEB J, May 1, 2004; 18(7): 828 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tan, F. N. Hutchison, and A. A. Jaffa Mechanisms of angiotensin II-induced expression of B2 kinin receptors Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H926 - H932. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cellier, M. Mage, J. Duchene, C. Pecher, R. Couture, J.-L. Bascands, and J.-P. Girolami Bradykinin reduces growth factor-induced glomerular ERK1/2 phosphorylation Am J Physiol Renal Physiol, February 1, 2003; 284(2): F282 - F292. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Baptista, M. C. W. Avellar, R. C. Araujo, J. L. Pesquero, J. P. Schanstra, J. L. Bascands, J. P. Esteve, A. C. M. Paiva, M. Bader, and J. B. Pesquero Transcriptional Regulation of the Rat Bradykinin B2 Receptor Gene: Identification of a Silencer Element Mol. Pharmacol., December 1, 2002; 62(6): 1344 - 1355. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Christopher, V. Velarde, D. Zhang, D. Mayfield, R. K. Mayfield, and A. A. Jaffa Regulation of B2-kinin receptors by glucose in vascular smooth muscle cells Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1537 - H1546. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |